secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001062993-26-002371
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit
--------------------------------------------------------------------------

- Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.
- R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.
- Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.
- INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.
- Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/0001062993-26-002371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-002371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer